Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 226

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies

Open access
Vicente Miranda, Hugo, Szegő, Éva M., Oliveira, Luís M. A., Breda, Carlo, Darendelioglu, Ekrem, de Oliveira, Rita M., Ferreira, Diana G., Gomes, Marcos A., Rott, Ruth, Oliveira, Márcia, Munari, Francesca, Enguita, Francisco J., Simões, Tânia, Rodrigues, Eva F., Heinrich, Michael, Martins, Ivo C., Zamolo, Irina, Riess, Olaf, Cordeiro, Carlos, Ponces-Freire, Ana, Lashuel, Hilal A., Santos, Nuno C., Lopes, Luisa V., Xiang, Wei, Jovin, Thomas M., Penque, Deborah, Engelender, Simone, Zweckstetter, Markus, Klucken, Jochen, Giorgini, Flaviano, Quintas, Alexandre, Outeiro, Tiago F.·2017·Brain

Abstract

α-Synuclein misfolding and aggregation is a hallmark in Parkinson’s disease and in several other neurodegenerative diseases known as synucleinopathies. The toxic properties of α-synuclein are conserved from yeast to man, but the precise underpinnings of the cellular pathologies associated are still elusive, complicating the development of effective therapeutic strategies. Combining molecular genetics with target-based approaches, we established that glycation, an unavoidable age-associated post-translational modification, enhanced α-synuclein toxicity in vitro and in vivo, in Drosophila and in mice. Glycation affected primarily the N-terminal region of α-synuclein, reducing membrane binding, impaired the clearance of α-synuclein, and promoted the accumulation of toxic oligomers that impaired neuronal synaptic transmission. Strikingly, using glycation inhibitors, we demonstrated that normal clearance of α-synuclein was re-established, aggregation was reduced, and motor phenotypes in Drosophila were alleviated. Altogether, our study demonstrates glycation constitutes a novel drug target that can be explored in synucleinopathies as well as in other neurodegenerative conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awx056

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 226

Metadata

Authors
Vicente Miranda, H., Szegő, É. M., Oliveira, L. M. A., Breda, C., Darendelioglu, E., de Oliveira, R. M., Ferreira, D. G., Gomes, M. A., Rott, R., Oliveira, M., Munari, F., Enguita, F. J., Simões, T., Rodrigues, E. F., Heinrich, M., Martins, I. C., Zamolo, I., Riess, O., Cordeiro, C., Ponces-Freire, A., Lashuel, H. A., Santos, N. C., Lopes, L. V., Xiang, W., Jovin, T. M., Penque, D., Engelender, S., Zweckstetter, M., Klucken, J., Giorgini, F., Quintas, A., & Outeiro, T. F.
Venue
Brain
Published
2017-04-10
Volume
140
Issue
5
Pages
1399-1419
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2604479317
Cited by
226
References
9
FWCI
9.27
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies. https://app.cochat.ai/papers/10.1093/brain/awx056
The paper
Vicente Miranda, H., Szegő, É. M., Oliveira, L. M. A., Breda, C., Darendelioglu, E., de Oliveira, R. M., Ferreira, D. G., Gomes, M. A., Rott, R., Oliveira, M., Munari, F., Enguita, F. J., Simões, T., Rodrigues, E. F., Heinrich, M., Martins, I. C., Zamolo, I., Riess, O., Cordeiro, C., . . . Outeiro, T. F. (2017). Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies. Brain. https://doi.org/10.1093/brain/awx056

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.